Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN – Get a rating) – Equity research analysts Cantor Fitzgerald dropped their fiscal 2022 earnings per share (EPS) estimates for Biohaven Pharmaceutical in a research note published Tuesday, April 26. Cantor Fitzgerald analyst C. Duncan now expects the company to earn ($6.85) per share for the year, down from his previous estimate of ($6.60).
A number of other analysts have also recently commented on BHVN. UBS Group raised its price target on Biohaven Pharmaceutical shares from $150.00 to $160.00 in a Tuesday, January 4, report. HC Wainwright reiterated a “buy” rating and issued a target price of $160.00 on Biohaven Pharmaceutical shares in a report on Friday, January 7. Morgan Stanley lowered its price target on shares of Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating on the stock in a Wednesday, April 6 report. Finally, Mizuho raised its price target on Biohaven Pharmaceutical shares from $144.00 to $154.00 and gave the stock a “buy” rating in a Thursday, March 3 report. Three analysts gave the stock a hold rating and eight gave the company a buy rating. According to data from MarketBeat, Biohaven Pharmaceutical currently has an average rating of “Buy” and an average price target of $148.27.
NYSE BHVN opened at $104.23 on Thursday. The company’s 50-day simple moving average is $117.61 and its 200-day simple moving average is $123.44. Biohaven Pharmaceutical has a 12-month low of $65.24 and a 12-month high of $151.51. The company has a market capitalization of $7.35 billion, a P/E ratio of -7.97 and a beta of 1.06.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its quarterly results on Friday, February 25. The company reported ($3.01) EPS for the quarter, missing analyst consensus estimates of ($2.07) by ($0.94). The company posted revenue of $190.01 million for the quarter, versus a consensus estimate of $175.54 million. In the same quarter last year, the company achieved EPS of ($3.62). The company’s quarterly revenue increased by 441.1% compared to the same quarter last year.
Hedge funds have recently been buying and selling shares of the company. Russell Investments Group Ltd. increased its position in Biohaven Pharmaceutical by 14.5% in the third quarter. Russell Investments Group Ltd. now owns 61,683 shares of the company worth $8,567,000 after acquiring an additional 7,791 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in Biohaven Pharmaceutical in the third quarter worth approximately $5,404,000. Montag A & Associates Inc. acquired a new stake in Biohaven Pharmaceutical in the third quarter valued at approximately $96,000. Balyasny Asset Management LLC purchased a new stake in Biohaven Pharmaceutical in the third quarter worth approximately $4,785,000. Finally, Teacher Retirement System of Texas increased its position in Biohaven Pharmaceutical by 40.3% in the third quarter. Teacher Retirement System of Texas now owns 9,254 shares of the company worth $1,285,000 after acquiring 2,660 additional shares in the last quarter. 91.73% of the shares are held by institutional investors.
About Biohaven Pharmaceutical (Get a rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
Get news and reviews for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.